3-iodobenzylguanidine has been researched along with yttrium radioisotopes in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grossman, AB; Kaltsas, GA; Mukherjee, JJ | 1 |
| Buscombe, JR | 1 |
| Lewington, VJ | 1 |
| Besse, IM; Bushnell, DL; Juweid, ME; Madsen, MT; Menda, Y; O'Dorisio, MS; O'Dorisio, T | 1 |
| An, R; Biersack, HJ; Gao, ZR; Zhang, YX | 1 |
| Antunovic, L; Bombardieri, E; Castellani, MR; Chiti, A; Fanti, S; Lopci, E; Pepe, G | 1 |
| Galt, JR; Halkar, R; Kendi, AT; Moncayo, VM; Nye, JA; Schuster, DM | 1 |
| Caplin, M; Cheung, VTF; Khoo, B; Nastos, K; Navalkissoor, S; Quigley, AM; Toumpanakis, C | 1 |
4 review(s) available for 3-iodobenzylguanidine and yttrium radioisotopes
| Article | Year |
|---|---|
The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Somatostatin; Yttrium Radioisotopes | 2001 |
Targeted radionuclide therapy for neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Peptides, Cyclic; Radiopharmaceuticals; Somatostatin; Yttrium Radioisotopes | 2003 |
Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.
Topics: 3-Iodobenzylguanidine; Antibodies, Monoclonal; Drug Therapy, Combination; Humans; Iodine Radioisotopes; Neoplasms; Positron-Emission Tomography; Radiation Dosage; Radioimmunotherapy; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes | 2011 |
Radionuclide Therapies in Molecular Imaging and Precision Medicine.
Topics: 3-Iodobenzylguanidine; Humans; Iodine Radioisotopes; Microspheres; Molecular Imaging; Molecular Targeted Therapy; Multimodal Imaging; Neoplasms; Precision Medicine; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Sodium Iodide; Yttrium Radioisotopes | 2017 |
1 trial(s) available for 3-iodobenzylguanidine and yttrium radioisotopes
| Article | Year |
|---|---|
[Targeted radionuclide therapy for patients with metastatic medullary thyroid carcinoma].
Topics: 3-Iodobenzylguanidine; Adult; Aged; Antineoplastic Agents; Carcinoma, Medullary; Female; Follow-Up Studies; Humans; Indium Radioisotopes; Male; Middle Aged; Octreotide; Pentetic Acid; Positron-Emission Tomography; Remission Induction; Thyroid Gland; Thyroid Hormones; Thyroid Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2006 |
3 other study(ies) available for 3-iodobenzylguanidine and yttrium radioisotopes
| Article | Year |
|---|---|
Interventional nuclear medicine in hepatocellular carcinoma and other tumours.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Carriers; Humans; Infusions, Intra-Arterial; Iodine Radioisotopes; Iodized Oil; Liver Neoplasms; Microspheres; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy, Adjuvant; Treatment Outcome; Yttrium Radioisotopes | 2002 |
Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
Topics: 3-Iodobenzylguanidine; Drug Therapy, Combination; Humans; Iodine Radioisotopes; Models, Biological; Neuroendocrine Tumors; Octreotide; Radiation Dosage; Radiopharmaceuticals; Yttrium Radioisotopes | 2006 |
Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
Topics: 3-Iodobenzylguanidine; Acute Kidney Injury; Adrenal Gland Neoplasms; Adult; Aged; Chemotherapy, Adjuvant; Female; Humans; Male; Middle Aged; Octreotide; Organometallic Compounds; Paraganglioma; Pheochromocytoma; Radiopharmaceuticals; Retrospective Studies; Yttrium Radioisotopes | 2017 |